9-ME-BC
9-Methyl-β-carboline
9-ME-BC (9-Methyl-β-carboline) is a cognitive & mood research compound. Beta-carboline that boosts dopamine synthesis and shows neurotrophic/anti-inflammatory effects on dopaminergic neurons.
9-ME-BC quick facts
| Reported research dose | 15mg-30mg |
| Route | Oral |
| Frequency | 1x Daily AM · 5 On 2 Off or Daily |
| Half-life | Short (~hours) |
| Forms | Oral |
| Evidence level | Animal |
Dopaminergic nootropic with a neuroprotective angle. Run in short blocks, not forever.
How 9-ME-BC works
Beta-carboline that boosts dopamine synthesis and shows neurotrophic/anti-inflammatory effects on dopaminergic neurons.
Proposed benefits
Researched for focus, memory, neuroprotection, mood and stress resilience.
Where to get 9-ME-BC
Buy 9-ME-BC at Disguised Alpha →The evidence for 9-ME-BC
Graded by what exists behind each claim.
Human clinical evidence
- No human trials: development stopped at preclinical, so the ceiling on any claim here is a rodent model — and these transfer poorly.
📊 Correlative data
- Small community use, mostly for mood and motivation. Reported experience is of a slow-building dopaminergic lift over weeks rather than an acute effect, which is consistent with a mechanism that acts on neuronal growth rather than transmitter release.
- Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.
🧪 How the mechanism reads
- A beta-carboline that in rodent and cell work acts as a weak MAO-A inhibitor, stimulates dopaminergic neurite outgrowth, and shows neuroprotective and anti-inflammatory effects in models of dopaminergic damage.
- The MAO inhibition is the interaction to know about, weak or not — it is the mechanism behind the caution against combining beta-carbolines with serotonergic drugs or tyramine-rich food.
Why an empty tier is not a verdict → · What community dosing logs are worth →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What 9-ME-BC actually does
9-Methyl-beta-carboline is a pyrido[3,4-b]indole with a single methyl group on the indole nitrogen, position 9. C12H10N2, 182.22 Da. That one methyl and its position are the entire compound, and the reason is at the end of this section.
Monoamine oxidase, with numbers instead of the word ‘weak’. Keller 2020 measured it: IC50 1 µM for MAO-A and 15.5 µM for MAO-B Keller 2020. That is roughly 15-fold selectivity for MAO-A, and 1 µM is not a trivial number — it is within the concentration range an oral dose can arithmetically reach (see the pharmacokinetics section below). MAO-A is the isoform that deaminates serotonin and noradrenaline and the one that metabolizes dietary tyramine in the gut wall. So the interaction profile of this compound is set by a measured enzyme constant, not by a vibe.
How it gets into a cell, and it is not the route you would guess. In midbrain and cortical astrocyte cultures, the effects of 9-me-BC were mediated by an organic cation transporter and explicitly not by the dopamine transporter Keller 2020. That is a specific carrier family — the same OCT system that carries metformin and cimetidine and that handles cationic drug secretion in kidney and liver — and it makes this molecule a plausible member of a competition that nobody has looked for.
What it turns on. In astrocytes, gene expression of artemin (Artn), BDNF, Egln1, Tgfb2 and Ncam1 rose, through the phosphatidylinositol 3-kinase pathway Keller 2020. In primary mesencephalic culture, the number of differentiated dopaminergic neurones rose, with induction of Shh, Wnt1, Wnt5a, En1, En2, Nurr1 and Pitx3 and of the markers Th, Dat and Aldh1a1; lactate dehydrogenase release, propidium iodide staining and caspase-3 activity all fell and ATP content rose Hamann 2008. A follow-up added tyrosine hydroxylase up-regulation in pre-existing neurons, induction of Gata2, Gata3, Creb1 and Crebbp, neurite outgrowth requiring protein kinases A and C, EGF receptor, FGF receptor and NCAM, protection against lipopolysaccharide, regeneration after chronic rotenone, inhibition of microglial proliferation and a fall in alpha-synuclein protein Polanski 2010.
Now the part that decides whether any of the above should reassure you. Methylating the other nitrogen — position 2, the pyridine nitrogen — converts a beta-carboline into a permanently charged quaternary carbolinium ion and a potent mitochondrial complex I inhibitor. 2,9-Dimethyl-beta-carbolinium occurs in human brain, raises reactive oxygen species, collapses mitochondrial membrane potential, activates caspases 3 and 7 by 24 hours and tips into late apoptosis or necrosis by 48; injected into rat substantia nigra it produced a dose-dependent fall in striatal dopamine, and the whole profile paralleled MPP+, the metabolite that causes MPTP parkinsonism Pavlovic 2006. 9-Me-BC is the direct precursor of that cation, one enzymatic N-methylation away. The same laboratory also showed 9-me-BC protects cultures against 2,9-dimethyl-beta-carboline toxicity Polanski 2010. Both facts are real, they point in opposite directions, and nobody has established which one wins in a person taking 20 mg a day for eight weeks.
Cell, rodent, human — and where it stops
In cells. Primary mesencephalic culture from rodent midbrain: more differentiated dopaminergic neurones, less LDH release, less caspase-3, more ATP, and anti-proliferative effects in the SH-SY5Y human neuroblastoma line Hamann 2008. Astrocyte culture: anti-proliferative without toxicity, neurotrophic gene induction, PI3K-dependent, OCT-mediated uptake, and the MAO IC50 values of 1 and 15.5 µM Keller 2020.
In rodents, and this is the strongest link. Gruss 2012 gave rats 9-me-BC for 10 days and reported improved spatial learning in the radial maze, elevated hippocampal dopamine, and elongated dendritic trees with higher spine numbers on dentate gyrus granule neurons Gruss 2012. That is a behavioral endpoint, a neurochemical endpoint and a structural endpoint in one study, which is more than most compounds on this site have. What the published abstract does not state is the route or the milligram dose, and that omission is exactly what stops the result being convertible into a human protocol.
In humans: nothing. No trial, no case series, no pharmacokinetic measurement, no published adverse-event report. The 15–30 mg oral figure on every vendor page is a community convention with no study behind it in either direction.
The obstacles, one at a time. (1) The headline cell effect is on differentiation, and an adult brain may have nothing to differentiate. Hamann's own paper says it could not determine whether the extra dopaminergic neurones came from precursor cells or from transdifferentiation Hamann 2008. Embryonic mesencephalic culture is full of precursors; an adult human substantia nigra is not. So the single most impressive result in this literature may have no substrate in the reader. (2) The rat study that does show a behavioral effect used hippocampal endpoints, not nigral ones Gruss 2012 — dopamine in hippocampus and dentate spines — which is a different claim from the anti-parkinsonian one the cell work supports, and the two have never been joined. (3) Everything turns on a concentration nobody has measured. MAO-A inhibition at 1 µM Keller 2020 is either the dominant effect of an oral dose or an irrelevance, depending on a human plasma number that does not exist. (4) Baseline is not zero. Beta-carbolines are present in cooked meat, tobacco smoke, coffee and alcohol and endogenously in blood, brain and CSF Gruss 2012 Hamann 2008, so any human study has to measure a rise above a diet-dependent background rather than an appearance from nothing.
9-ME-BC pharmacokinetics — how much of it actually gets in
The catalog says ‘Short (~hours)’. No published human pharmacokinetic measurement exists for this molecule, so here is the arithmetic that bounds it.
The bound that matters. 9-Me-BC is 182.22 Da. A 20 mg oral dose is 110 µmol. If all of it were absorbed instantly and distributed evenly through roughly 42 L of total body water with no protein binding and no clearance, the whole-body concentration would be about 2.6 µM. That is the ceiling, and real peak plasma levels will be some fraction of it. Set it beside the measured constants: MAO-A IC50 1 µM, MAO-B IC50 15.5 µM Keller 2020. So partial MAO-A inhibition at 20 mg is arithmetically reachable and meaningful MAO-B inhibition is not, by an order of magnitude. That single comparison is the most useful thing anyone can say about dosing this compound, and it is a bound rather than a measurement.
What clears it, and the one route that is not clearance. A small, planar, lipophilic aromatic amine of 182 Da crosses membranes and the blood-brain barrier by passive diffusion — unlike the charged peptides elsewhere in this catalog, it does not need a transporter to get in, though the organic cation transporter is what moves it into astrocytes Keller 2020. Elimination should be hepatic oxidation and conjugation. The exception is the route that is not elimination at all: N-methylation at position 2 produces a permanently charged quaternary carbolinium Pavlovic 2006, and a permanent cation does not diffuse back out of a cell or across the blood-brain barrier. A metabolite that cannot leave is the opposite of clearance, and it is the specific pharmacokinetic reason this compound's long-term profile cannot be inferred from its short-term one.
The oral barrier. No absolute bioavailability, no food effect, no first-pass fraction has been published. What can be said: the rat study that produced a behavioral effect dosed for 10 days Gruss 2012, and a compound that reached brain badly enough to be inert would not have moved hippocampal dopamine. That sets a floor on absorption and nothing more.
Route. Oral only, in every protocol anybody runs. There is no injectable form and no reason to invent one, because the molecule's size and lipophilicity are already favorable — the unknown is metabolic fate, and changing the route does not change that.
What would have to be true, and how you would know it was not
Four predictions. The first is a home experiment; the third argues against the compound.
1. A tyramine load should raise blood pressure more on this than off it. If a 20 mg dose reaches even a fraction of the 2.6 µM ceiling, MAO-A is partially inhibited at an IC50 of 1 µM Keller 2020, and partial gut-wall MAO-A inhibition is exactly what produces the pressor response to aged cheese and cured meat. Protocol: the same tyramine-rich meal, home blood pressure at 30, 60 and 90 minutes, once off the compound and once on it at steady state. A systolic rise of more than 15 mmHg beyond the off-drug day means the MAO inhibition is real at human doses. This has never been done and it costs a cuff and two dinners.
2. Prolactin should fall, not rise. Dopamine is the tonic inhibitor of pituitary prolactin release, and both the MAO-A inhibition Keller 2020 and the rise in hippocampal and striatal dopamine Gruss 2012 Hamann 2008 point the same way. Draw prolactin at baseline and at 4 weeks, fasting and before 10am, avoiding a draw after nipple stimulation or a seizure-like event, both of which move it far more. A rise would mean the dopaminergic story is wrong in a person.
3. Against the product: MoCA will not move in a healthy adult. The rodent result is improved radial-maze learning with new dendritic spines Gruss 2012; the cell result is more differentiated dopaminergic neurones Hamann 2008. Both describe plasticity in tissue that is either young or damaged. A 35-year-old with intact cognition has a ceiling effect on every bedside test, so a null result on MoCA would not falsify the mechanism — which is precisely why anyone claiming a cognitive benefit from this compound has no way to demonstrate it, and should say so.
4. High-sensitivity CRP should drift down slightly, and homocysteine should not move. The anti-inflammatory arm is real in culture — microglial proliferation inhibited, inflammatory cytokine expression reduced Polanski 2010 — so hs-CRP at 8 weeks is the cheapest systemic test of whether any of it is happening outside a dish. Homocysteine is on the list as the control: N-methylation consumes S-adenosylmethionine and generates homocysteine, so if this molecule were being methylated at any metabolically significant rate, homocysteine would be the marker that noticed. At 20 mg (110 µmol) against a daily methylation flux measured in millimoles it should be invisible — and if it is not, that is the most interesting abnormal result anybody could produce on this compound.
What nobody has tested yet
Five experiments. The second one is the reason this page is worth reading.
1. No human has ever had a plasma level measured. One 20 mg dose, LC-MS/MS at 8 time points over 24 hours, one volunteer. That single run would decide whether the 1 µM MAO-A IC50 Keller 2020 is a real interaction risk or a laboratory number, and it would be the first human pharmacokinetic data that exists for this compound.
2. Nobody has looked for 2,9-dimethyl-beta-carbolinium in a person taking 9-me-BC. The cation is a known human brain constituent and a complex I inhibitor as potent as MPP+ Pavlovic 2006; the precursor is now being swallowed daily by people who found it on a forum; the analytical method is already published in that same paper. Measuring urinary and plasma 2,9-dimethyl-beta-carbolinium before and during a course is the single most important unrun experiment on this page, and it is unrun because the two literatures — the neuroprotection one and the neurotoxin one — are written by the same group and still have never been put in the same protocol.
3. Nobody has identified the enzyme that would do that methylation in a human. The chemistry is a single N-methyl transfer from S-adenosylmethionine onto a pyridine nitrogen. Which methyltransferase, at what rate, and whether it is inducible are all unknown, and the answer would tell you whether the risk is negligible, dose-dependent or individual.
4. Nobody has run it on adult rather than embryonic dopaminergic tissue. Every stimulation result in this literature comes from primary cultures rich in precursors Hamann 2008 Polanski 2010. Repeating the same protocol on adult-derived cultures or on human iPSC-derived neurons that have been fully differentiated first would separate ‘makes new neurones’ from ‘makes existing neurones healthier’, which are two completely different products.
5. Nobody has checked the organic cation transporter interaction. Keller identified OCT-mediated uptake as the route into astrocytes Keller 2020. Metformin, cimetidine and a long list of cationic drugs are OCT substrates. Whether 9-me-BC competes with them — in the gut, the kidney or the brain — is a standard transporter assay nobody has commissioned, and metformin is the single most co-taken drug in this audience.
9-ME-BC — its own safety story, not its class's
The class block is written for the racetam shelf. Four things here are this molecule's own.
1. The MAO-A number turns a vague caution into a named list. An IC50 of 1 µM Keller 2020 means the compounds to keep away from it are the ones that raise synaptic serotonin: SSRIs, SNRIs, tramadol, dextromethorphan, triptans, St John's wort, MDMA. And the food rule is the tyramine rule — aged cheese, cured and fermented meats, soy sauce, tap beer, over-ripe fruit. This is not the generic ‘check with a pharmacist’ line; it is a specific enzyme with a measured constant, and it is the most actionable safety fact on the page.
2. The carbolinium question, stated without alarm and without dismissal. N2-methylation of this molecule yields a dopaminergic neurotoxin that is found in human brain, inhibits complex I and behaves like MPP+ Pavlovic 2006; the same compound also protects cultures against that cation Polanski 2010. Nobody has measured which effect dominates in a person. The honest position is that a molecule marketed for dopaminergic neuroprotection is a single methyl group away from a dopaminergic neurotoxin, that this is a chemical fact rather than a reported harm, and that a person running long courses is doing an experiment whose most important readout has never been collected.
3. It is anti-proliferative, and that is not automatically good. 9-Me-BC inhibited proliferation of SH-SY5Y neuroblastoma cells Hamann 2008 and of astrocytes without toxicity Keller 2020. Slowing glial proliferation is the mechanism behind the anti-inflammatory claim; it is also a description of suppressing the cells that repair the brain after injury. Nobody has studied what months of that does.
4. The dose has no provenance and the supply has a measured problem. The 15–30 mg range appears in no study. Meanwhile, analytical work on cognitive-enhancement supplements found label quantities inaccurate in 75% of cases, with some products delivering up to four-fold more than a typical pharmacologic dose Cohen 2021, and a market surveillance study run by 12 official medicines control laboratories across Europe and Australia documented 34 distinct unauthorized nootropic molecules in 159 samples, 69% of them from the illegal market Vanhee 2025. For a compound whose MAO-A threshold sits at the same order of magnitude as its own dose, a four-fold label error is not a rounding problem.
Sources read for this page
- Keller S, Polanski WH, Enzensperger C, Reichmann H, Hermann A, Gille G. 9-Methyl-β-carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytes. Journal of Neural Transmission (Vienna) 2020;127(7):999-1012 · PMID 32285253
- Hamann J, Wernicke C, Lehmann J, Reichmann H, Rommelspacher H, Gille G. 9-Methyl-β-carboline up-regulates the appearance of differentiated dopaminergic neurones in primary mesencephalic culture. Neurochemistry International 2008;52(4-5):688-700 · PMID 17913302
- Polanski W, Enzensperger C, Reichmann H, Gille G. The exceptional properties of 9-methyl-β-carboline: stimulation, protection and regeneration of dopaminergic neurons coupled with anti-inflammatory effects. Journal of Neurochemistry 2010;113(6):1659-1675 · PMID 20374418
- Gruss M, Appenroth D, Flubacher A, Enzensperger C, Bock J, Fleck C, Gille G, Braun K. 9-Methyl-β-carboline-induced cognitive enhancement is associated with elevated hippocampal dopamine levels and dendritic and synaptic proliferation. Journal of Neurochemistry 2012;121(6):924-931 · PMID 22380576
- Pavlovic S, Schulze G, Wernicke C, Bonnet R, Gille G, Badiali L, Kaminska A, Lorenc-Koci E, Ossowska K, Rommelspacher H. 2,9-Dimethyl-β-carbolinium, a neurotoxin occurring in human brain, is a potent inducer of apoptosis as 1-methyl-4-phenylpyridinium. Neuroscience 2006;139(4):1525-1537 · PMID 16517085
- Cohen PA, Avula B, Wang YH, Zakharevich I, Khan I. Five Unapproved Drugs Found in Cognitive Enhancement Supplements. Neurology: Clinical Practice 2021;11(3):e303-e307 · PMID 34484905
- Vanhee C, Deconinck E, George M, Hansen A, Hackl A, Wollein U, El-Atma O, Beerbaum N, Aureli F, Borioni A, et al. The Occurrence of Illicit Smart Drugs or Nootropics in Europe and Australia and Their Associated Dangers: Results from a Market Surveillance Study by 12 Official Medicines Control Laboratories. Journal of Xenobiotics 2025;15(3):88 · PMID 40558871
9-ME-BC — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- This class is broad, but the predicted problems cluster by mechanism rather than by molecule. Cholinergics (racetams, and anything raising acetylcholine) predict headache — the classic one, from choline demand outrunning supply. Dopaminergics and eugeroics predict tolerance, sleep disruption and a flat mood on the days off. Anything glutamatergic or AMPA-facing carries a theoretical excitotoxicity concern at high doses.
- The pattern worth internalizing: anything that borrows performance from tomorrow eventually presents the bill. Sleep is the most common currency it gets paid in.
What has actually been reported
- Headache is the most reported effect across the racetam family and usually responds to added choline.
- Irritability, blunted affect and a rebound low on cessation are commonly reported with the stimulant-adjacent members.
- Most of this class has little or no controlled human safety data at the doses actually used.
How to reduce the risk
Same mechanism as the prediction.
- Take a choline source with any racetam. The headache is the mechanism running out of substrate, and it is largely preventable rather than something to push through.
- Dose in the morning. Almost everything in this class has a longer functional tail than its half-life suggests, and sleep is the first thing you lose.
- Use them for something, not as a habit. The compounds that carry tolerance genuinely reward intermittent use aimed at a task, and genuinely punish daily use aimed at feeling normal.
- One at a time, and long enough to judge it. This is the class where people stack five and cannot tell you which one is doing anything — and the effects are subjective, so attribution is already hard enough.
- If you need it to feel normal, stop. That is the line where a tool has become a dependency, and it is the one worth watching for.
What it does to your bloodwork
A fact about the assay.
- No routine marker tracks these. Sleep is the assay — if it is degrading, the compound is costing more than it is producing, and that shows up before anything else does.
Don't run this if
- A seizure history — several of these lower the threshold at least theoretically, and it is not worth establishing empirically.
- Bipolar disorder, for the dopaminergic members especially.
- Alongside prescribed psychiatric medication without knowing exactly how the mechanisms overlap.
The honest unknown
- Chronic use is essentially uncharacterized. The specific unmeasured thing is what daily cholinergic or dopaminergic pressure does to baseline function over years — not whether a few weeks is tolerable.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
9-ME-BC — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What 9-ME-BC moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Most of this class has no predicted marker movement at all, and saying so is more useful than listing markers that will not move.
What to do: A baseline liver panel is reasonable for anything taken daily and long-term. Beyond that there is nothing specific to chase.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — 9-ME-BC in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside 9-ME-BC
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease imitates every cognitive complaint there is |
| Vitamin B12 | Deficiency causes fog long before it causes anemia |
| Methylmalonic Acid (MMA) | Catches the deficiency a normal B12 hides |
| Ferritin | Low iron flattens cognition at levels most labs call fine |
| Vitamin D (25-Hydroxy) | Commonly low, cheap to correct, associated with mood |
The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.
Check results you already have → · All 103 markers A–Z
9-ME-BC — frequently asked questions
What is 9-ME-BC?
9-ME-BC (9-Methyl-β-carboline) is a cognitive & mood research compound. Beta-carboline that boosts dopamine synthesis and shows neurotrophic/anti-inflammatory effects on dopaminergic neurons.
Is the full 9-ME-BC protocol on this page?
The reported research dose is on this page, along with how 9-ME-BC works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of 9-ME-BC?
9-ME-BC has an approximate half-life of Short (~hours), which is part of what determines how often it's dosed.
What's the evidence behind 9-ME-BC?
Current evidence level: Animal. 9-ME-BC is offered for research purposes only and is not an approved medicine.
9-ME-BC inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What 9-ME-BC is used for
9-ME-BC appears under 1 goal in the goal router.
Related Cognitive & Mood compounds
Where this goes next
9-ME-BC is the glutamatergic arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.